Former Intercept CEO to take the helm at Altimmune Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 5 December, 2025

If reaching biopharma’s most influential decision-makers is a 2026 priority, this live Q&A will show you where Endpoints is headed — and how brands are turning that reach into impact. Join founder and CEO Arsalan Arif for an insider session built for marketing and communications professionals. Register now.

presented by Writ­ing the Next Chap­ter in CLL Care: Bridg­ing Gaps Through In­no­va­tion and In­sights

spotlight Exclusive: Trump administration pushes end-of-term deadline for ‘most favored nation’ promises

news Praxis stops pivotal trial of rare epilepsy drug early for efficacy German court stops Merck from selling subcutaneous Keytruda in patent battle with Halozyme Peer Review Ex-Intercept CEO takes over at Altimmune; Carolyn Bertozzi leaves Alnylam's board

Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

endpoints pharma Prasad's claim of 10 Covid vaccine deaths may be an overcount, FDA sources say ACIP once again postpones vote on hepatitis B birth dose, now set for Friday BioNexus gets $500M to step into manufacturing; Thermo Fisher, AtomVie expand

in case you missed it 1. Nationwide Children’s gene therapy shows early promise after Taysha pullback 2. In reciprocal licensing pact with Kelun, Crescent's PD-1xVEGF heads to China 3. Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron 4. ARCH, Lilly Asia Ventures return to back US-China startup SciNeuro 5. Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen 6. News Briefing UniQure restates FDA's negative feedback on Huntington's trial; Neurimmune's expanded AstraZeneca alliance 7. China’s scientific clout is growing as US influence wanes: the data show how